Teva Pharmaceutical Industries Limited
TEVA

$25.06 B
Marketcap
$22.09
Share price
Country
$-0.32
Change (1 day)
$22.17
Year High
$10.34
Year Low

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

marketcap

P/E ratio for Teva Pharmaceutical Industries Limited (TEVA)

P/E ratio as of 2023: -21.16

According to Teva Pharmaceutical Industries Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -21.16. At the end of 2022 the company had a P/E ratio of -4.26.

P/E ratio history for Teva Pharmaceutical Industries Limited from 1985 to 2023

PE ratio at the end of each year

Year P/E ratio
2023 -21.16
2022 -4.26
2021 22.92
2020 -2.61
2019 -10.80
2018 -7.44
2017 -1.18
2016 105.77
2015 35.16
2014 15.88
2013 26.72
2012 16.50
2011 13.61
2010 14.13
2009 24.78
2008 52.62
2007 18.16
2006 43.01
2005 25.51
2004 55.15
2003 22.16
2002 25.87
2001 33.40
2000 60.99
1999 73.17
1998 124.46
1997 84.51
1996 116.90
1995 106.54
1994 118.26
1993 129.89
1992 220.02
1991 269.78
1990 334.01
1989 350.71
1988 501.02
1986 517.67
1985 1008.10